Search Results - "Turke, Alexa B."

MEK Inhibition Leads to PI3K/AKT Activation by Relieving a Negative Feedback on ERBB Receptors by TURKE, Alexa B, SONG, Youngchul, COSTA, Carlotta, COOK, Rebecca, ARTEAGA, Carlos L, ASARA, John M, ENGELMAN, Jeffrey A

“…The phosphoinositide 3-kinase (PI3K)/AKT and RAF/MEK/ERK signaling pathways are activated in a wide range of human cancers. In many cases, concomitant…”
Get full text

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors by Sequist, Lecia V, Waltman, Belinda A, Dias-Santagata, Dora, Digumarthy, Subba, Turke, Alexa B, Fidias, Panos, Bergethon, Kristin, Shaw, Alice T, Gettinger, Scott, Cosper, Arjola K, Akhavanfard, Sara, Heist, Rebecca S, Temel, Jennifer, Christensen, James G, Wain, John C, Lynch, Thomas J, Vernovsky, Kathy, Mark, Eugene J, Lanuti, Michael, Iafrate, A John, Mino-Kenudson, Mari, Engelman, Jeffrey A

“…Lung cancers harboring mutations in the epidermal growth factor receptor (EGFR) respond to EGFR tyrosine kinase inhibitors, but drug resistance invariably…”
Get more information

Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC by Turke, Alexa B., Zejnullahu, Kreshnik, Wu, Yi-Long, Song, Youngchul, Dias-Santagata, Dora, Lifshits, Eugene, Toschi, Luca, Rogers, Andrew, Mok, Tony, Sequist, Lecia, Lindeman, Neal I., Murphy, Carly, Akhavanfard, Sara, Yeap, Beow Y., Xiao, Yun, Capelletti, Marzia, Iafrate, A. John, Lee, Charles, Christensen, James G., Engelman, Jeffrey A., Jänne, Pasi A.

“…MET amplification activates ERBB3/PI3K/AKT signaling in EGFR mutant lung cancers and causes resistance to EGFR kinase inhibitors. We demonstrate that MET…”
Get full text

Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathways by Rothenberg, S Michael, Concannon, Kyle, Cullen, Sarah, Boulay, Gaylor, Turke, Alexa B, Faber, Anthony C, Lockerman, Elizabeth L, Rivera, Miguel N, Engelman, Jeffrey A, Maheswaran, Shyamala, Haber, Daniel A

“…Treatment of EGFR-mutant lung cancer with erlotinib results in dramatic tumor regression but it is invariably followed by drug resistance. In characterizing…”
Get full text

PIKing the right patient by Turke, Alexa B, Engelman, Jeffrey A

“…HER2 amplification and PIK3CA mutation were validated as biomarkers for sensitivity to the single-agent phosphoinositide 3-kinase (PI3K) inhibitor, GDC-0941,…”
Get full text

Using Tandem Mass Spectrometry in Targeted Mode to Identify Activators of Class IA PI3K in Cancer by XUEMEI YANG, TURKE, Alexa B, ASARA, John M, JIE QI, YOUNGCHUL SONG, REXER, Brent N, MILLER, Todd W, JÄNNE, Pasi A, ARTEAGA, Carlos L, CANTLEY, Lewis C, ENGELMAN, Jeffrey A

“…Phosphatiditylinositide-3-kinase (PI3K) is activated in some cancers by direct mutation, but it is activated more commonly in cancer by mutation of upstream…”
Get full text

A Cross-Species Study of PI3K Protein-Protein Interactions Reveals the Direct Interaction of P85 and SHP2 by Breitkopf, Susanne B., Yang, Xuemei, Begley, Michael J., Kulkarni, Meghana, Chiu, Yu-Hsin, Turke, Alexa B., Lauriol, Jessica, Yuan, Min, Qi, Jie, Engelman, Jeffrey A., Hong, Pengyu, Kontaridis, Maria I., Cantley, Lewis C., Perrimon, Norbert, Asara, John M.

“…Using a series of immunoprecipitation (IP) – tandem mass spectrometry (LC-MS/MS) experiments and reciprocal BLAST, we conducted a fly-human cross-species…”
Get full text

EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib by Corcoran, Ryan B, Ebi, Hiromichi, Turke, Alexa B, Coffee, Erin M, Nishino, Michiya, Cogdill, Alexandria P, Brown, Ronald D, Della Pelle, Patricia, Dias-Santagata, Dora, Hung, Kenneth E, Flaherty, Keith T, Piris, Adriano, Wargo, Jennifer A, Settleman, Jeffrey, Mino-Kenudson, Mari, Engelman, Jeffrey A

“…BRAF mutations occur in 10-15% of colorectal cancers (CRCs) and confer adverse outcome. While RAF inhibitors such as vemurafenib (PLX4032) have proven…”
Get more information

Abstract 4773: Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6 dependent survival pathways by Rothenberg, Stephen Michael, Concannon, Kyle, Cullen, Sarah, Turke, Alexa B., Faber, Anthony C., Engelman, Jeffrey A., Maheswaran, Shyamala, Haber, Daniel A.

“…Abstract Treatment of EGFR-mutant lung cancer with erlotinib results in dramatic tumor regression but it is invariably followed by drug resistance. In…”
Get full text

Abstract PR8: Insensitivity to RAF inhibition by vemurafenib in BRAF mutant colorectal cancer by EGFR-mediated reactivation of MAPK signaling by Corcoran, Ryan B., Hung, Kenneth E., Flaherty, Keith T., Piris, Adriano, Wargo, Jennifer A., Settleman, Jeffrey, Mino-Kenudson, Mari, Engelman, Jeffrey A., Ebi, Hiromichi, Turke, Alexa B., Coffee, Erin M., Nishino, Michiya, Cogdill, Alexandria P., Brown, Ronald D., Pelle, Patricia Della, Dias-Santagata, Dora

“…Abstract BRAF mutations occur in 10–15% of colorectal cancers (CRCs) and confer adverse outcome in the metastatic setting. While RAF inhibitors such as…”
Get full text

Abstract LB-350: EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition by vemurafenib by Corcoran, Ryan B., Ebi, Hiromichi, Turke, Alexa B., Coffee, Erin M., Nishino, Michiya, Cogdill, Alexandra P., Brown, Ronald D., Dias-Santagata, Dora, Pelle, Patricia Della, Hung, Kenneth E., Flaherty, Keith T., Piris, Adriano, Wargo, Jennifer A., Settleman, Jeffrey, Mino-Kenudson, Mari, Engelman, Jeffrey A.

“…Abstract Oncogenic BRAF mutations occur in 10-15% of colorectal cancers (CRCs) and confer adverse outcome. While RAF inhibitors such as vemurafenib (PLX4032)…”
Get full text

Pre-existence and clonal selection of MET amplification in EGFR mutant NSCLC by Turke, Alexa B., Zejnullahu, Kreshnik, Wu, Yi-Long, Song, Youngchul, Dias-Santagata, Dora, Lifshits, Eugene, Toschi, Luca, Rogers, Andrew, Mok, Tony, Sequist, Lecia, Lindeman, Neal I., Murphy, Carly, Akhavanfard, Sara, Yeap, Beow Y., Xiao, Yun, Capelletti, Marzia, Iafrate, A. John, Lee, Charles, Christensen, James G., Engelman, Jeffrey A., Jänne, Pasi A.

“…MET amplification activates ERBB3/PI3K/AKT signaling in EGFR mutant lung cancers, and causes resistance to EGFR kinase inhibitors. We demonstrate that MET…”
Get full text